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Conclusion: Obtained results do not permit to form robust 
conclusion concerning role of RT in the management of 
thymic tumors patient. Besides clear, unquestionable bad 
prognostic factors as bad PS, low differentiation, presence of 
local relapse, lung fibrosis, second malignancy or distant 
metastases, we found only one more - male sex, decreasing 
LC. 
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Purpose or Objective: In a UK Medical Research Council trial 
carried out before the widespread use of chemotherapy or 
CT-PET, palliative thoracic radiotherapy delivering 39 Gy in 
13 daily fractions conferred an overall survival (OS) benefit 
when compared to 17 Gy in 2 weekly fractions in good 
performance status patients with radically treatable NSCLC. 
To determine whether this benefit persisted with 
contemporary standards of staging and systemic therapy, we 
studied the outcomes of patients with locally 
advanced/metastatic NSCLC receiving palliative radiotherapy 
in our centre over a 2 year period. 
 
Material and Methods: The case records of 176 patients who 
received palliative thoracic radiotherapy in 2011 or 2012 
were reviewed retrospectively. Data collected included age, 
stage, performance status, dose/fractionation, additional 
treatments and survival. 
 
Results: 36 patients received high dose thoracic radiotherapy 
(HDTRT, 36-40 Gy in 12-15 fractions) and 140 received a 
lower dose (LDTRT), 20 Gy in 5 fractions. Median OS in the 
HDTRT group was 8.5 months and 5.5 months in the LDTRT 
group (hazard ratio 0.6, p <0.01). 12 patients received 
chemotherapy and HDTRT with median OS 12m vs 7m in the 
25 patients receiving chemotherapy and LDTRT. In those who 
received HDTRT alone, median OS was 6.5m vs 4m for LDTRT 
alone. In patients with stage II-III disease median OS was 
9.6m vs 6m for LDTRT. In those with stage IV disease, median 
OS was 8m for HDTRT vs 5m for LDTRT. In patients with 
performance status 0-2 median OS was 9m for HDTRT vs 6m 
for LDTRT, while in the two patients with performance status 
3 who were irradiated it was 1m with HDTRT vs 3m with 
LDTRT. 
 
Conclusion: This audit of contemporary practice suggests 
that the survival benefit of high dose palliative radiotherapy 
reported by Macbeth (Clin Oncol (R Coll Radiol). 1996;8:167-
75) persists with modern staging and systemic therapy 
practices, and may also extend to patients with small volume 
stage IV disease excluded from that trial, but not those with 
poor performance status. 
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Purpose or Objective: SBRT is the standard treatment of 
early stage inoperable NSCLC. Parenchymal changes (PC) 
after SBRT make it difficult the differential diagnosis 
between treatment effects and disease recurrence. The 
purpose of our study was to identify the radiographic 
features (High Risk Features: HRFS) with high specificity (SP) 
and sensitivity (SE) for early detection of recurrence. 
 
Material and Methods: We retrospectively evaluated patients 
treated with SBRT for inoperable early stage NSCLC. Median 
dose was 50 Gy in 5 fractions (range, 45-60 Gy /3-12 
fractions) prescribed to 80% isodose. All patients underwent 
chest computed tomography (CT) before SBRT and after 3, 6, 
12 months (thereafter annually). Using a chest CT scan 
radiological aspects according to Huang et al. classification 
(Huang et al., Radiother Oncol 2013;109:51-57) were 
evaluated. 18F FDG-PET was used in case of suspected tumor 
recurrence. 
 
Results: Forty-five patients were included, 34 males and 11 
females; mean age was 75.7 years (range, 60-86 years); 
77.8% of patients had stage IA disease and 22.2% stage IB 
with a mean follow-up of 21 months, local control was 69%. 
Benign acute CT changes (up to 6 months after SBRT) were 
observed in 34 patients (patchy consolidation was the most 
frequent) and late changes (after 6 months) in 44 patients 
(mass-like fibrosis was the most frequent). HRFs were 
identified in 20 patients, enlarging opacity at primary site in 
9 patients, enlargement after 12 months in 20 patients, 
bulging margin in 7 patients, disappearance of linear margin 
in 2 patients, loss of air bronchogram in 18 patients and 
cranial-caudal growth in 15 patients. These HRFs were 
individually significantly associated with local recurrence of 
the disease. The better predictor of relapse was enlargement 
opacity at 12 months (p <0.001) with SE: 84.6% and SP: 
71.8%. The presence of > 1 HRFS demonstrated a higher SE 
(93.3%) (p <0.02) with SP: 59.4%. 
 
Conclusion: Detection of HRFS is predictive of relapse with a 
SE increasing with the number of observed HRFs. This 
observation allows to better define the diagnostic algorithm 
in follow-up, suggesting to perform further exams only in 
patients with > 1 HRFS. 
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Purpose or Objective: Because there is a positive correlation 
between radiation dose and local control (LC) in non-small 
cell lung cancer (NSCLC) although with no impact on overall 
survival (OS) our institutional protocol allowed moderate 
radiotherapy dose escalation up to 70 - 74 Gy (BED: 84 - 88.8 
Gy) on the standard 60-66 Gy (BED: 72 - 79.2 Gy) providing 
that organs-at-risk are keep in tolerance. This retrospective 
study aims to assess the impact of dose escalation in clinical 
outcome when the duration of radiotherapy is taken in to 
account through the use of BED model corrected by time 
(tBED) 
 
Material and Methods: 78 consecutively patients with 
unresectable NSCLC were retrospectively analyzed. All were 
PET-CT staged and were treated with platinum-based 
chemotherapy (either concomitant or sequential) and 3DCRT. 
Two groups were compared according to prescribed dose 
level: Standard Dose Group (SD) n = 38 those receiving 
nominal prescribed BED ≤ 79.2 Gy and Escalated Dose Group 
(ED) n = 40 those receiving > nominal prescribed BED >79.2 
Gy. For both groups actual administered dose corrected for 
the duration of treatment (tBED) was calculated using the 
formula [tBED (Gy) = n d (1+d/ α/β) – KT] (Sinclair, IJROBP 
1999. 44:381) Multivariate Cox regression analysis was 
performed to identify significant predictors of OS, Disease 
Free Survival (DFS) and Thoracic Progression Free Survival 
(TPFS). For purposes of comparison a nominal prescribed 
dose of 60 Gy @2Gy in 39 days have a tBED = 44, 7 Gy. 
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Results: For the entire group median follow-up and overall 
survival (OS) were: 17.7 months (mo) (IQR: 10.3-27.9) and 
19.1 mo (95% CI 13.9-24.3). Median tBED for entire group was 
45.8 Gy (IQR 40.5-49) tBED in SD and ED group were 42.2 (IQR 
37.4-45.2) and 48.9 Gy (IQR 45.7-49.7) Univariate analysis by 
groups: Actuarial median OS: SD vs. ED was: 17 mo (95% CI 
13.6-20.3) vs. 22.3 mo (95% CI 9.6-35) p = 0.18. Actuarial 
median DFS SD vs. ED was: 8.3 (95% IC 7.2 – 9.3) vs. 12.8 mo 
(95% IC 3 – 22.7) p = 0.009. Actuarial median TPFS (mo) SD vs. 
ED was: 8.4 (95% CI 7.2-9.5) vs. 21.8 (95% CI 13.2-30.5) p = 
0.003.  
On multivariate analysis significant predictors for OS, DFS and 
TPFS are depicted on table: radiotherapy dose was found not 
to be a significant factor.  
 
 
 
Conclusion: On univariate analysis, but not on multivariate, 
ED associated statistically significant better DFS and TPFS 
and non-statistically significant better OS, even when 
adjusted to overall treatment time. Due to treatment time 
delays SD group received a suboptimal dose of radiotherapy 
and ED group received a tBED which virtually match nominal 
60 Gy. Our data in agreement with those resulting from 
randomized trials strongly support that 60 Gy @2 Gy with 
stringent control of time delays is the gold standard in the 
radiotherapy for NSCLC. 
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Purpose or Objective: Radiotherapy with or without 
chemotherapy is commonly used for isolated loco-regional 
recurrence of non-small cell lung cancer (NSCLC) after initial 
surgery. This study was undertaken to evaluate the outcomes 
and complications of curative radiotherapy for locoregionally 
recurrent NSCLC. 
 
Material and Methods: Medical records of 57 patients who 
received curative radiotherapy for locoregionally recurrent 
NSCLC without distant metastasis after surgery from 2004 to 
2014 were retrospectively reviewed. At the time of 
recurrence, the median age was 67 years (range 34-81 years), 
and most patients (84.2%) have good ECOG performance 
status. All patients initially received a curative intent 
operation, and the median disease-free interval was 14 
months. For locoregionally recurrent lung cancer, forty-two 
patients were treated with concurrent chemoradiotherapy 
(CCRT), and 15 patients with radiotherapy alone. Radiation 
dose ranged from 45 Gy to 70 Gy (median 66 Gy) by a three-
dimensional conformal technique. Lung function change after 
radiotherapy was evaluated by comparing pulmonary function 
tests before and after radiotherapy. 
 
Results: Median follow-up after recurrence was 20 months. 
Six patients showed a complete response, and 39 patients 
showed a partial response. The median survival was 30 
months. Two-year locoregional recurrence-free survival 
(LRFS), distant metastasis-free survival (DMFS), disease-free 
survival (DFS) and overall survival (OS) rate were 46.1%, 
37.2%, 31.9%, and 65.1%, respectively. Eleven patients 
showed disease progression within the radiation field after 
radiotherapy. Pulmonary function decreased meaningfully 
after radiotherapy, and radiation pneumonitis of any grade 
was seen in 19 patients. In the multivariate analysis, age 
under 70 years was associated with good OS (p=0.047); 
concurrent chemoradiotherapy with good OS (p=0.014), and 
DFS (p=0.003); and single-station recurrence with good OS 
(p=0.01), DFS (p=0.022), and LRFS (p=0.01). 
 
Conclusion: Patients who have locoregionally recurrent 
NSCLC showed favorable survival outcomes with salvage 
radiotherapy. However, lung function should be carefully 
evaluated before and after radiotherapy. Young age, single 
site recurrence, and the use of CCRT were good prognostic 
factors of overall survival. In patients with good prognostic 
factors and suitable for curative radiotherapy, CCRT could be 
considered to improve treatment outcomes. 
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Purpose or Objective: Precise delineation of primary lung 
cancer mass and involved mediastinal LN is very important 
requirement in order to improve radiotherapy outcome and 
minimize treatment toxicity. Diffusion weighted MRI (DW-
MRI) is a recently introduced functional imaging modality, 
having higher sensitivity and specificity than CT to 
differentiate lung cancer from post-obstructive lobar collapse 
. And also able to pinpoint lymph nodes with and without 
metastasis. The apparent diffusion coefficient (ADC) is the 
quantitative parameter of DW-MRI with cut off value 1.4 x 
103 mm2/s which can be used as a good tool to contour 
Target volumes in lung cancer. 
the aim is to study the feasibility of using the images of DW-
MRI and data of ADC map for radiotherapy contouring 
purposes 
 
Material and Methods: Twenty cases of newly diagnosed lung 
cancer patients underwent CT chest with contrast and 
respiratory gatted DW-MRI with b value of 0, 500, 1000s/mms 
. Both studies were obtained in the same position, respiratory 
phase and slice thickness (5mm) in order to allow proper 
image fusion. For each patient, we’ve delineated GTV for 
primary lung mass and GTV- LN for involved mediastinal LN 
on both CT scan (guided by size) and DW-MRI (guided by T2W 
and the ADC map ) together with delineation of the nearby 
risk structures. Auto margins were taken for the CTV and the 
PTV. The impact of using MRI on stage and different treated 
volumes was assessed and compared. 
 
 
